Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 9183
Country/Region: Uganda
Year: 2015
Main Partner: The AIDS Support Organization
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $6,939,143 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,272,754
Care: TB/HIV (HVTB) $335,419
Care: Pediatric Care and Support (PDCS) $402,731
Laboratory Infrastructure (HLAB) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $249,466
Testing: HIV Testing and Counseling (HVCT) $413,877
Sexual Prevention: Other Sexual Prevention (HVOP) $29,113
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $255,793
Treatment: Adult Treatment (HTXS) $2,807,031
Treatment: Pediatric Treatment (PDTX) $172,959
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 26,064
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 2,644
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 50,887
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 3,149
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 82,744
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 82,744
CARE_NEW Aggregated Age/sex: <15 Female 2016 233
CARE_NEW Aggregated Age/sex: <15 Male 2016 209
CARE_NEW Aggregated Age/sex: 15+ Female 2016 4,063
CARE_NEW Aggregated Age/sex: 15+ Male 2016 2,205
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 6,710
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 6,710
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 6,710
FN_THER Aggregated Age: <18 2016 751
FN_THER Aggregated Age: 18+ 2016 1,212
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 1,963
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 24,727
FN_THER Sum of Aggregated Age disaggregates 2016 1,963
GEND_GBV Number of people receiving post-GBV care 2016 4,261
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 4,731
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 6,703
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 3,573
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 5,057
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 55,203
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 91,778
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 36,940
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 60,081
HTS_TST By Test Result: Negative 2016 37,944
HTS_TST By Test Result: Negative 2016 32,316
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 100,447
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 163,619
HTS_TST Sum of Aggregated Age/Sex <15 2016 8,304
HTS_TST Sum of Aggregated Age/Sex <15 2016 11,760
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 92,143
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 151,859
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 100,447
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 163,619
HTS_TST Sum of Test Result disaggregates 2016 100,447
HTS_TST Sum of Test Result disaggregates 2016 163,619
HTS_TST_POS By Test Result: Positive 2016 62,503
HTS_TST_POS By Test Result: Positive 2016 131,303
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2016 6,644
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2016 6,644
LAB_CAP By clinical laboratories 2016 11
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 11
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 2,245
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 1,190
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,245
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 1,190
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 2,015
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 1,055
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 230
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 135
PMTCT_ARV Sum of New and Current disaggregates 2016 2,245
PMTCT_ARV Sum of New and Current disaggregates 2016 1,190
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 859
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 93
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 952
PMTCT_EID Sum of Infant Age disaggregates 2016 952
PMTCT_STAT By: Known positives at entry 2016 2,022
PMTCT_STAT By: Known positives at entry 2016 1,051
PMTCT_STAT By: Number of new positives identified 2016 223
PMTCT_STAT By: Number of new positives identified 2016 139
PMTCT_STAT Number of new ANC and L&D clients 2016 41,060
PMTCT_STAT Number of new ANC and L&D clients 2016 23,058
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 35,894
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 20,842
PMTCT_STAT Sum of Positives Status disaggregates 2016 2,245
PMTCT_STAT Sum of Positives Status disaggregates 2016 1,190
PP_PREV Age/sex: 10-14 Female 2016 4,276
PP_PREV Age/sex: 10-14 Female 2016 786
PP_PREV Age/sex: 10-14 Male 2016 3,347
PP_PREV Age/sex: 10-14 Male 2016 94
PP_PREV Age/sex: 15-19 Female 2016 14,422
PP_PREV Age/sex: 15-19 Female 2016 874
PP_PREV Age/sex: 15-19 Male 2016 10,433
PP_PREV Age/sex: 15-19 Male 2016 483
PP_PREV Age/sex: 20-24 Female 2016 21,614
PP_PREV Age/sex: 20-24 Female 2016 884
PP_PREV Age/sex: 20-24 Male 2016 12,010
PP_PREV Age/sex: 20-24 Male 2016 662
PP_PREV Age/sex: 25-49 Female 2016 31,153
PP_PREV Age/sex: 25-49 Female 2016 1,613
PP_PREV Age/sex: 25-49 Male 2016 20,585
PP_PREV Age/sex: 25-49 Male 2016 1,291
PP_PREV Age/sex: 50+ Female 2016 2,053
PP_PREV Age/sex: 50+ Female 2016 164
PP_PREV Age/sex: 50+ Male 2016 157
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 121,558
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 7,008
PP_PREV Sum of Age/Sex disaggregates 2016 121,558
PP_PREV Sum of Age/Sex disaggregates 2016 7,008
TB_ART Aggregated Age: <15 2016 78
TB_ART Aggregated Age: 15+ 2016 1,095
TB_ART Female 2016 754
TB_ART Male 2016 419
TB_ART Sum of Aggregated Age disaggregates 2016 1,173
TB_ART Sum of Sex disaggregates 2016 1,173
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 1,462
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 1,173
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 5,804
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 77,055
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 82,744
TB_SCREEN Sex: Female 2016 54,108
TB_SCREEN Sex: Male 2016 28,751
TB_SCREEN Sum of Aggregated Age disaggregates 2016 82,859
TB_SCREEN Sum of Sex disaggregates 2016 82,859
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 82,859
TX_CURR Aggregated Age/Sex: 15+ Female 2016 4,936
TX_CURR Aggregated Age/Sex: 15+ Female 2016 22,867
TX_CURR Aggregated Age/Sex: 15+ Male 2016 10,727
TX_CURR Aggregated Age/Sex: 15+ Male 2016 49,680
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 16,907
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 78,312
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 15,663
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 72,547
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 15,663
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 72,547
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 3,813
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 8,040
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 12,359
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 11,853
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 8,627
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 10,163
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 23
VMMC_CIRC By circumcision technique: Surgical VMMC 2016 7,147
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 7,147
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 1,572
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 7,018
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 129
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 7,147
Cross Cutting Budget Categories and Known Amounts Total: $2,425,000
Motor Vehicles: Purchased $425,000
Gender: Gender Based Violence (GBV) $800,000
Post GBV Care
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Gender: Gender Equality $400,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Key Populations: Sex Workers $800,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention